Oral rebamipide is redesigned for colon retention in ulcerative colitis
A new oral nanoformulation aims to solve one of the central pharmacologic problems in inflammatory bowel disease: getting a drug to survive the stomach, stay in the intestine long enough, and remain concentrated at inflamed colonic tissue. The platform packages rebamipide inside mucin DEAE-dextran armored nanoparticles built on a caprylic acid and 6-O-stearoyl ascorbic acid core. In practical terms, the design tries to do three jobs at once — protect the cargo from gastric degradation, help it adhere to mucus, and keep it present at the disease site rather than clearing rapidly through the gut.
The strategy fits the biology of ulcerative colitis. Inflamed mucosa is exposed, mucus is disrupted, and rapid transit can wash away conventional oral therapies before they reach the distal colon. A carrier that binds to the mucosal surface and resists gastric conditions could, in theory, keep an anti-inflammatory agent in contact with the bowel wall long enough to matter. This formulation was built around that logic.
A pH-stable carrier with prolonged mucosal binding
The nanoparticles maintained structural integrity in gastric conditions and showed pH-independent stability. They also demonstrated strong mucosal binding in the colon, with intestinal retention extending up to 48 hours. That is a meaningful pharmaceutical property in a disease where dwell time often determines whether an oral agent acts locally or is lost to transit.
One sentence captures the central engineering goal: the carrier stayed intact in acid and then clung to the colon.
This is where the material design becomes clinically relevant. DEAE-dextran brings a positive charge, which favors electrostatic interaction with the negatively charged inflamed mucosal surface. Mucin coating adds another layer of biological compatibility, while the core structure appears to support the encapsulated drug through the gastric environment. The result is not just a delivery vehicle, but a system designed to exploit the altered mucosal chemistry of inflammation.
Inflammation markers fell while barrier repair signals rose
Therapeutic testing showed that oral administration of M@D@Re-SCNPs reduced colonic inflammatory status more strongly than free rebamipide. The formulation lowered expression of NF-κB, COX-2, iNOS, and PI3K, all of which sit inside major inflammatory and immune-signaling pathways relevant to colitis. Suppressing those pathways matters because persistent activation drives cytokine release, oxidative stress, leukocyte recruitment, and tissue injury across the bowel wall.
The effect was not limited to inflammatory silencing. Encapsulated rebamipide also promoted Muc2 production, which supports mucus layer regeneration and goblet cell viability. In ulcerative colitis, the mucus barrier is not a cosmetic layer; it is a functional defense that separates luminal bacteria and irritants from the epithelium. Improving Muc2 expression could therefore help restore a damaged first-line barrier while dampening the inflammatory cycle that keeps the mucosa injured.
Why rebamipide becomes more relevant when it reaches the colon intact
Rebamipide already has a biologic profile that makes it attractive for intestinal inflammation. It is known for anti-inflammatory, antioxidant, and mucosal protective effects, and it can promote goblet cell proliferation and mucin secretion. The limitation has been delivery, not concept. Low oral bioavailability and inadequate lower-colon retention blunt its usefulness for inflammatory bowel disease.
The nanoparticle format appears to address that bottleneck by controlling where and how long the drug is released. Sustained exposure at the inflamed site can help keep local signaling pathways suppressed rather than allowing a brief systemic pulse that fades before the mucosa repairs. In colitis, duration of contact is often as important as potency, because the bowel is renewing and shedding mucus continuously while the inflammatory process pushes in the opposite direction.
Colitis outcomes improved in the animal model
In the dextran sulfate sodium colitis model, treatment with M@D@Re-SCNPs improved the disease phenotype. Body weight retention was better, colon length was preserved more effectively, goblet cells were maintained, and immune-cell infiltration was reduced. These are not abstract endpoints; they reflect the core clinical consequences of active colitis, including catabolism, structural shortening of the colon, epithelial damage, and immune-driven tissue injury.
The pattern is coherent with the biomarker data. A formulation that stays in place longer, suppresses inflammatory signaling, and helps rebuild mucin production would be expected to reduce mucosal damage and preserve tissue architecture. The animal findings line up with that sequence.
The carrier also showed high cytocompatibility and no observable toxicity in major organs. For a nanomedicine intended for chronic gastrointestinal disease, that safety signal is essential, because repeated oral exposure is likely to be part of any real-world treatment pathway.
What this formulation could change for oral IBD therapy
The main appeal of this approach is that it attacks several failures of standard oral therapy at once. It protects the drug from the upper GI tract, concentrates delivery in the colon, extends retention at inflamed tissue, and couples anti-inflammatory action with mucosal repair. For ulcerative colitis, that combination is attractive because treatment success depends not only on dampening inflammation, but also on restoring the epithelial and mucus barriers that prevent relapse.
A one-size-fits-all oral tablet cannot easily solve the competing problems of degradation, transit, and local targeting. This nanoformulation was designed specifically around those barriers, and the experimental results support the concept in a preclinical setting. The mechanistic readout is especially important: lower NF-κB, COX-2, iNOS, and PI3K expression suggests that the formulation is influencing the inflammatory machinery rather than simply masking symptoms.
The remaining issue is translation. These data come from a colitis model, not from patients with ulcerative colitis, and the clinical performance of the system still has to be established in human disease. Dose selection, reproducible colonic targeting, long-term tolerability, and scale-up manufacturing will all shape whether the platform can move beyond proof of concept. For now, the study shows that rebamipide can be re-engineered into a colon-retentive oral carrier with measurable anti-inflammatory and barrier-restorative activity in experimental colitis.